Human Signal · Cheap Truth · Clean Rights · Market Pull
Find the drugs everyone else stopped looking at.
HiveProspect filters stranded clinical-stage assets down to the opportunities worth investigating, then shows you why they survived, what remains unknown, who appears to control them, what prior work still counts, and what the next trustworthy answer may cost.
Discard almost everything. Investigate the survivors.
HiveProspect does not help you search more. It helps you discard almost everything and investigate the few opportunities that survive.
01
Discovered assets
A source-backed lead enters the queue.
↓
02
Human Signal
Convincing human evidence in the right indication?
↓
03
Cheap Truth
A practical path to the next decisive answer?
↓
04
Clean Rights
A credible path to sufficient transferable rights?
↓
05
Market Pull
A valuable problem with a defensible opportunity?
↓
06
Why Stranded?
Did the drug fail, or did the company/trial fail?
↓
07
ACTIONABLE OPPORTUNITIES
Evidence, rights and next-decision diligence — before capital.
Screening sequence shown, not a claim that this queue has cleared every gate. UNKNOWN is not a pass.
877 active trial–asset rows in the local candidate queue. These are not 877 unique or qualified opportunities. Gate-survivor totals are not published until the underlying assessments are adjudicated.
Evidence before conviction
See what a disciplined first look reveals.
Genuine cached trial-level leads, not cleared acquisitions. These examples show why UNKNOWN matters.
Funding, recruitment, strategy, formulation and clinical biology are different failure modes. HiveProspect keeps them separate, with the evidence and uncertainty attached.
A financing problem can justify another look. It cannot prove a drug works. A well-executed negative clinical result must still carry weight.
The document may resolve part of the chain. Transfer scope and encumbrances still need checking.
Next action: review title and data-transfer rights. No automatic price change, outreach or purchase. This is not a real company event.
Trust before conviction
Every conclusion should survive a source check.
Source facts, model inferences and unknowns remain distinct. A publication is not proof of efficacy. A trial sponsor is not automatically the current owner. Prior spend is not present value.